Overview

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2026-11-16
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche